Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
View MissionIR's Instablogs on:
  • PowerSecure International, Inc. (POWR) Receives Contracts Worth $15 Million For Power Projects

    PowerSecure International is a leading provider of energy and utility technologies to electric utilities and their industrial, commercial, and institutional customers. The company provides products and services in the areas of: energy efficiency, interactive distributed generation, and utility infrastructure.

    The company announced today that it has received $15 million worth of new contracts for its Interactive Distributed Generation (IDG) smart grid power systems and utility infrastructure projects. The new IDG system awards total $10 million and include installations for hospitals and data centers along with pharmaceutical and industrial facilities. The utility infrastructure contracts total $5 million and include transmission system and substation projects for utilities and large industrial customers.

    All of these contract awards are for turnkey sales of products and services. PowerSecure states that approximately 80 percent of the revenue is expected to be realized in the second half of 2012, adding to the revenue backlog for the company. The remaining 20 percent of the revenue from these contracts will be recognized during the first half of 2013.

    The CEO of PowerSecure, Sidney Hinton, was very pleased with the recent contract awards particularly with the "continuing traction in the hospital, data center, and pharmaceutical markets." He added that the "sales and marketing teams focused on these customer categories are making terrific progress." The company continues to be bullish on the opportunities it has to serve these large and growing markets with its proprietary IDG solutions.

    For further information about PowerSecure International and its IDG products and services, please visit the company's website at www.powersecure.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Tags: POWR
    Jun 27 2:02 PM | Link | Comment!
  • Curis, Inc. (CRIS) Announces Clinical Cancer Research Journal To Publish CUDC-907 Data

    Curis, a drug development company focused on developing proprietary targeted medicines for cancer treatment, announced today an article regarding CUDC-907 has been published in the journal Clinical Cancer Research. CUDC-907 is an orally-available small molecule drug candidate under development by Curis, and it is designed to simultaneously inhibit PI3K and HDAC. Several members of Curis' scientific team authored the article, titled "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase (HDAC) activity and phosphatidylinositol 3-kinase (PI3K) signaling." The article will be published in the print version of the journal in the near future.

    "We are encouraged by the publication of CUDC-907 data in Clinical Cancer Research. We believe that these data support our development strategy for this molecule, under which we plan to initiate a Phase I clinical trial in patients with diffuse large B-cell lymphoma or multiple myeloma later this year," stated Dan Passeri, Curis President and Chief Executive Officer. "We developed CUDC-907 to target PI3K as well as HDAC, which is known to induce multiple epigenetic modifications affecting signaling networks and also to act synergistically with PI3K inhibitors. The objective of CUDC-907 is to provide for a broad disruption of several pathways that are implicated in hematologic malignancies in order to achieve a better outcome for patients."

    The focus of the article was CUDC-907's potential for continued development in cancer treatment, specifically in the treatment of hematological cancers. CUDC-907 has shown potent anticancer activity in xenograft models and cultured cancer cells, as well as evidence that it may offer therapeutic benefits for multiple cancer types through broad signaling network disruption. A specific example of these promising capabilities is data showing that CUDC-907 durably inhibits both the primary P13K-AKT-mTOR pathway and also many compensatory signaling molecules which cancer cells often utilize to outmaneuver the mechanisms of single target kinase inhibitors, including RAF, MEK, MAPK, and STAT-3, among others. The scientists at Curis believe that CUDC-907 could possibly deliver improved therapeutic benefit with its simultaneous, sustained disruption of multiple signaling pathways.

    Curis' discovery and development efforts are focused on building a portfolio of small molecule network-targeted inhibitors against a wide range of cancer types. The leading compounds within Curis' research and development programs are designed to inhibit one or more cancer targets, including EGFR, Her2, and PI3K, as well as the inhibition of histone deacetylase, or HDAC, a validated non-kinase cancer target. Each target combination is chosen for its potential of mechanistic synergy, offering a differentiated, potential breakthrough approach to cancer therapy, intended to disrupt cancer resistance networks.

    For more information, please visit www.curis.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Tags: CRIS
    Jun 26 2:21 PM | Link | Comment!
  • Year-End 1500 For S&P 500? What It Will Take To Crack March Highs

    A handful of four primary vectors were drawn up today by the chief investment strategist over at Wells Capital Management, Jim Paulsen, in an interview on his 1,500 target for the S&P 500. In an opening salvo against market crisis neuroses, Paulsen pegged Europe as no longer being a crisis in any proper sense, as the cyclical nature he predicts will be evinced once again at the European Summit this week. The argument is that Europe is basically a "chronic problem."

    Europe is a problem that will be with us for decades, but not one that will derail a global recovery Paulsen argues, pointing more to emerging markets like China and India which have seen bad growth metrics recently, and arguing that the biggest substantial risk to markets at this point, especially the S&P 500, would be a recession in the emerging world. However, the caveat here is obviously last Fall's strong, accommodative policy measures (easing, etc. as opposed to the late 2010 rate hikes) and the projection that China's slowdown is already bottoming-out, with a potential nadir being around Q4.

    The probability curve is pretty clear to Paulsen on such policy initiatives already getting ahead of the problems at some level, ensuring that the growth potential in emerging markets isn't something to be too worried about. So if the Euro fear flare up cycle is largely digestible and emerging markets can pull out of the dive easily enough, the other two major factors from Paulsen's point of view are an under-quantified robustness in the domestic economy coupled with exceptional earnings multiples.

    Pointing to $100-level trailing 12-month earnings per share estimate for the S&P 500 in a recent research note, that gives us a price-earnings multiple of around 13 times on trailing earnings (year-end consensus-estimated earnings of around 12.3 times), Paulsen confidently characterized it as a cheap buying opportunity. In fact, he characterized Europe as such and argues generally that too much of an internationalism bent exists, where too much focus on external economies in Europe and China for instance, has upset domestic perspectives.

    Paulsen made a strong case that the initial overstatement of U.S. growth data, followed by a huge failure to adequately state the realities of the problem, effectively short-circuited perceptions to a large extent, and he remains very bullish on the domestic economy. People may be selling the market based on low GDP projections but Paulsen argues the U.S. economy is doing "far better than people think," pointing to his own figure of around 2.5% growth, and underlining several elements that could push it as high as 3%. Stimulating factors cumulatively make this possible according to Paulsen, like mortgage rates under 3.75% (5% last year), money growth at around 10% since Fall (was growing at only 5% a year ago), a dollar that is still off 10% from 2010 highs, falling prices at the pump on fuel, and the recent Case-Shiller 20-city Index (Mar - April period) which shows a 1.3% jump in home prices, breaking a seven-month down trend streak.

    Also noted was the inflation rate falling from 4% last Fall to 1.7%, which, alongside China being able to buck the down trend and interest rates being so low amid prime earnings multiples, gives credence to the argument that the S&P 500 could rally through March highs of 1,440 in the second half of the year. Paulsen said that the combination of low interest rates/inflation and choice earnings multiples has never been seen before in the post-War era.

    The component vector is tactile to Paulsen who argues that investors aren't going to care about Europe with a modest domestic recovery and returning emergent growth, with only China's reliance on Europe as an export market raising concerns.

    Looking for a momentum pickup in emerging markets next year, upward revision of GDP targets, a settling-down of financial fear in the Euro zone, and underscoring the attractiveness of the S&P 500 valuations, Paulsen held fast on his 1,500 target for year-end.

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Jun 26 2:20 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.